SAN FRANCISCO, April 20, 2017 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) today announced that it will host
an analyst and investor event with clinical investigators on
Saturday, June 3, 2017 at
6:00 pm CDT in Chicago, IL during the 2017 American Society
of Clinical Oncology (ASCO) Meeting. The event will include a
presentation and discussion of updated clinical data for the
company's CD122-biased agonist, NKTR-214.
Data from two studies of NKTR-214 will be reviewed at the event,
including the Phase 1 dose-escalation study of NKTR-214 in
combination with nivolumab in patients with melanoma, renal cell
carcinoma and non-small cell lung cancer (PIVOT-02); and the Phase
1 study of monotherapy NKTR-214 in patients with advanced solid
tumors (EXCEL).
Presenters will include Dr. Adi
Diab, Assistant Professor, Melanoma Medical Oncology at the
University of Texas MD Anderson Cancer
Center, Dr. Nizar Tannir, Professor,
Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center and
Dr. Michael Hurwitz, Assistant
Professor of Medicine (Medical Oncology) at Yale Cancer Center.
NKTR-214 is an investigational immuno-stimulatory therapy
designed to expand specific cancer-fighting CD8+ effector T cells
and natural killer (NK) cells directly in the tumor
micro-environment and increase expression of PD-1 on these immune
cells. NKTR-214 targets CD122 specific receptors found on the
surface of these cancer-fighting immune cells in order to stimulate
their proliferation. In preclinical studies, treatment with
NKTR-214 resulted in a rapid expansion of these cells and
mobilization into the tumor micro-environment.1,2
NKTR-214 has an antibody-like dosing regimen similar to the
existing checkpoint inhibitor class of approved medicines.
Investors and analysts are invited to listen to a live audio
webcast of the presentation at
http://edge.media-server.com/m/p/guf8mqwk. The event will
also be available for replay for two weeks on the company's
website, www.nektar.com.
For those interested in attending this event in person, please
contact jsievers@nektar.com. Please RSVP in advance as seating is
limited.
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage
biopharmaceutical company whose mission is to discover and develop
innovative medicines to address the unmet medical needs of
patients. Our R&D pipeline of new investigational medicines
includes treatments for cancer, auto-immune disease and chronic
pain. We leverage Nektar's proprietary and proven chemistry
platform in the discovery and design of our new therapeutic
candidates. Nektar is headquartered in San Francisco,
California, with additional
operations in Huntsville, Alabama and Hyderabad,
India. Further information about
the company and its drug development programs and capabilities may
be found online at http://www.nektar.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements which can be
identified by words such as: "will," "designed" and similar
references to future periods. Examples of forward-looking
statements include, among others, statements we make regarding the
expected benefits of NKTR-214 as monotherapy and in combination
with other immunotherapy agents including nivolumab.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, anticipated
events and trends, and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict and many of which are outside of our
control. Our actual results may differ materially from those
indicated in the forward-looking statements. Therefore, you should
not rely on any of these forward-looking statements. Important
factors that could cause our actual results to differ materially
from those indicated in the forward-looking statements include,
among others: (i) NKTR-214 is in early stage clinical development
and the risk of failure remains high and failure can unexpectedly
occur at any stage for one or more of the cancer indications being
studied prior to regulatory approval due to lack of sufficient
efficacy, safety considerations or other factors that impact drug
development; (ii) scientific discovery of new medical breakthroughs
is an inherently uncertain process and the future success of
potential new drug candidates such as NKTR-214 is therefore very
uncertain and unpredictable and could fail; and (iii) certain other
important risks and uncertainties set forth in Nektar's Annual
Report on Form 10-K for the year ended December 31, 2016 filed with the Securities and
Exchange Commission on March 1, 2017.
Any forward-looking statement made by us in this press release is
based only on information currently available to us and speaks only
as of the date on which it is made. We undertake no obligation to
update any forward-looking statement, whether written or oral, that
may be made from time to time, whether as a result of new
information, future developments or otherwise.
Contact:
For Investors:
Jennifer Ruddock of Nektar Therapeutics
415-482-5585
Jodi Sievers of Nektar Therapeutics
415-482-5593
1. Charych, D., et al., Cancer Res. 2013;73(8
Suppl):Abstract nr 482 and Data on file.
2. Hoch U, at al. AACR; Mol Cancer Ther. 2013;12(11
Suppl):Abstract nr B296.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-to-host-analyst--investor-event-at-2017-asco-annual-meeting-300442693.html
SOURCE Nektar Therapeutics